26.08.2023 17:06:58
|
Amgen : Olpasiran Phase 2 Data Shows Continued Reduction Of Lp(a) Nearly A Year After Last Dose
(RTTNews) - Amgen (AMGN) said it presented data from the final analysis of the Phase 2 OCEAN-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.
Results from the OCEAN(a)-DOSE Phase 2 study announced in November of 2022 showed that doses of olpasiran greater than or equal to 75 mg Q12W reduced patients' Lp(a) by more than 95% at week 36. The results from the off-treatment extension period show that patients previously dosed with greater than or equal to 75 mg of olpasiran sustained about 40-50% placebo-adjusted percent reduction in Lp(a) nearly a year after the last dose. No new safety concerns were identified during the off-treatment extension period.
In addition, the study was the first to explore the effects of olpasiran on a key biomarker strongly associated with atherosclerosis, pro-atherogenic OxPL-apoB. During the treatment period, olpasiran showed a dose-dependent reduction in pro-atherogenic OxPL-apoB.
For More Such Health News, visit rttnews.com
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Amgen Inc.mehr Nachrichten
05.02.25 |
Börse New York in Grün: NASDAQ 100 zum Ende des Mittwochshandels mit Kursplus (finanzen.at) | |
05.02.25 |
Gute Stimmung in New York: So performt der Dow Jones am Mittwochnachmittag (finanzen.at) | |
05.02.25 |
Optimismus in New York: NASDAQ 100 im Plus (finanzen.at) | |
05.02.25 |
Pluszeichen in New York: Dow Jones verbucht am Mittag Zuschläge (finanzen.at) | |
05.02.25 |
Börse New York in Grün: NASDAQ 100 legt mittags zu (finanzen.at) | |
05.02.25 |
Amgen-Aktie steigt trotzdem: Amgen verzeichnet Gewinneinbruch (dpa-AFX) | |
05.02.25 |
Börse New York in Rot: Dow Jones präsentiert sich zum Start leichter (finanzen.at) | |
05.02.25 |
Anleger in New York halten sich zurück: NASDAQ 100 beginnt Handel mit Verlusten (finanzen.at) |
Analysen zu Amgen Inc.mehr Analysen
Aktien in diesem Artikel
Amgen Inc. | 283,40 | -1,00% |
|